Drug Profile


Alternative Names: GP 47680; KIN-493; NPC 04; Oxacarbazepine; TRI 476; Trileptal

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Novartis
  • Developer Novartis; Queen Mary University of London
  • Class Antiepileptic drugs; Dibenzazepines; Small molecules
  • Mechanism of Action Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Epilepsy
  • Phase II Multiple sclerosis
  • Discontinued Bipolar disorders; Diabetic neuropathies; Neurological disorders

Most Recent Events

  • 04 Jul 2016 Registered for Epilepsy in Japan (PO)
  • 15 Mar 2016 Biomarkers information updated
  • 01 Oct 2014 Phase-II clinical trials in Multiple sclerosis in United Kingdom (PO) (NCT02104661)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top